Related Experiment Video
Updated: Jun 17, 2025

In Vivo Functional Study of Disease-associated Rare Human Variants Using Drosophila
Published on: August 20, 2019
Heterozygous de novo dominant negative mutation of REXO2 results in interferonopathy
Elina Idiiatullina1,2,3, Mahmoud Al-Azab1,4, Meng Lin1
1Department of Genetics and Endocrinology, Guangzhou Institute of Paediatrics, Guangzhou Women and Children's Medical Centre, Guangzhou Medical University, Guangzhou, China.
Abstract:
Mitochondrial RNA (mtRNA) in the cytosol can trigger the innate immune sensor MDA5, and autoinflammatory disease due to type I IFN. Here, we show that a dominant negative mutation in the gene encoding the mitochondrial exonuclease REXO2 may cause interferonopathy by triggering the MDA5 pathway. A patient characterized by this heterozygous de novo mutation (p.T132A) presented with persistent skin rash featuring hyperkeratosis, parakeratosis and acanthosis, with infiltration of lymphocytes and eosinophils around small blood vessels. In addition, circulating IgE levels and inflammatory cytokines, including IFNα, are found consistently elevated. Transcriptional analysis highlights a type I IFN gene signature in PBMC. Mechanistically, REXO2 (T132A) lacks the ability to cleave RNA and inhibits the activity of wild-type REXO2. This leads to an accumulation of mitochondrial dsRNA in the cytosol, which is recognized by MDA5, leading to the associated type I IFN gene signature. These results demonstrate that in the absence of appropriate regulation by REXO2, aberrant cellular nucleic acids may accumulate and continuously trigger innate sensors, resulting in an inborn error of immunity.
Insights
A rare REXO2 gene mutation causes interferonopathy by allowing mitochondrial RNA to activate the MDA5 immune sensor. This leads to a type I interferon signature and an inborn error of immunity.
Area of Science:
- Immunology
- Genetics
- Molecular Biology
Background:
- Mitochondrial RNA (mtRNA) in the cytosol can activate the MDA5 innate immune sensor, leading to type I interferon production and autoinflammatory diseases.
- Dysregulation of mitochondrial homeostasis is implicated in various autoinflammatory conditions.
Purpose of the Study:
- To investigate the role of a dominant-negative mutation in the mitochondrial exonuclease REXO2 in causing interferonopathy.
- To elucidate the molecular mechanism by which REXO2 mutations trigger the MDA5 pathway.
Main Methods:
- Clinical phenotyping of a patient with a heterozygous de novo REXO2 mutation (p.T132A).
- Analysis of skin biopsy, circulating IgE, inflammatory cytokines (including IFNα), and peripheral blood mononuclear cell (PBMC) transcriptional profiles.
- Biochemical assessment of REXO2 (T132A) enzymatic activity and its effect on wild-type REXO2 function.
Main Results:
- The patient presented with a characteristic skin rash, elevated IgE, and consistently high levels of inflammatory cytokines, including IFNα.
- Transcriptional analysis of PBMCs revealed a type I interferon gene signature.
- The REXO2 (T132A) mutation impaired RNA cleavage activity, inhibited wild-type REXO2, and led to cytosolic accumulation of mitochondrial dsRNA, activating the MDA5 pathway.
Conclusions:
- A dominant-negative mutation in REXO2 can cause interferonopathy by disrupting mitochondrial RNA processing and triggering MDA5-mediated type I interferon production.
- Aberrant accumulation of cellular nucleic acids due to impaired REXO2 function results in continuous innate sensor activation, leading to an inborn error of immunity.
- This study highlights REXO2 as a critical regulator in preventing autoinflammation driven by endogenous RNA.
Related Concept Videos
Exon Recombination
Exon shuffling follows “splice frame rules.” Each exon...
Pleiotropy
Incomplete Dominance
Genetic Lingo
RNA Interference
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
Epistasis

